2,000
Participants
Start Date
January 1, 2002
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Platinum based chemotherapy
q1-3W according to physician's preference
Paclitaxel based chemotherapy
q1-3W according to physician's preference
Radiotherpay
40-50Gy/1.8-2.2Gy/20-25f
Surgery
Radical esophagectomy
Immunotherapy
Anti-PD-1/PD-L1 Antibody
5-FU Analog based chemotherpay
W1-5 qW or d1-14, q3W according to physician's preference
Nimotuzumab
200-400mg, d1,qW
RECRUITING
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER